Sierra Oncology, Inc. (SRRA) News

Sierra Oncology, Inc. (SRRA)

Today's Latest Price: $14.01 USD

0.13 (0.94%)

Updated May 29 4:00pm

Add SRRA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

Filter SRRA News Items

SRRA News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest SRRA News From Around the Web

Below are the latest news stories about Sierra Oncology Inc that investors may wish to consider to help them evaluate SRRA as an investment opportunity.

Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO

Company also exceeds offering target Continue reading...

Yahoo | April 21, 2020

Sierra Oncology Reports 2019 Year End Results

Sierra Oncology Reports 2019 Year End Results

Yahoo | March 3, 2020

Why Earnings Season Could Be Great for Sierra Oncology (SRRA)

Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Yahoo | February 26, 2020

Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call

VANCOUVER , Feb. 26, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its financial results for 2019 will be released on Tuesday, March 3 prior to market open. The management team from Sierra, at 8:00 a.m. ET , will host a conference call to discuss the company's progress made in 2019 and its plans for 2020. Call registration is available through the Sierra Oncology website at www.sierraoncology.com.

Yahoo | February 26, 2020

Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Building MOMENTUM for Patients with Myelofibrosis" at the Cowen 40th Annual Health Care Conference in Boston, Massachusetts.

Yahoo | February 25, 2020

The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ...

Benzinga | February 11, 2020

Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead

/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1,…

PR Newswire | February 6, 2020

The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Kodiak Sciences Inc (NASDAQ: KOD ) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) (announced positive results for a Phase 2 study of its drug to treat Friedreich ataxia) Relmada Therapeutics Inc (NASDAQ: RLMD ) ( announced positive Phase 2 results for drug to treat treatment-resistant depression) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 15) Auris Medical Holding Ltd (NASDAQ: EARS ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) C...

Benzinga | October 16, 2019

The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) Viela Bio Incn (NASDAQ: VIE ) (IPOed on Thursday) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 3) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) bluebird bio Inc . (NASDAQ: BLUE ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) DelMar Pharmaceuticals Inc (NASDAQ: DMP ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Erytech Pharma SA (NASDAQ: ERYP ) Frequency Therapeutics Inc (NASDAQ: FREQ )(IPOed on Thursday) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Jaguar Health Inc (NASDAQ: JAGX ) Karu...

Benzinga | October 4, 2019

Did Sierra Oncology, Inc. (NASDAQ:SRRA) Insiders Buy Up More Shares?

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be…

Yahoo Finance | July 15, 2019



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6173 seconds.